Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990, SHE:002422) obtained approval for an investigational new drug application for the clinical trial of SKB565 from China's National Medical Products Administration.
The drug is being developed for the treatment of advanced solid tumors, according to a Monday Hong Kong bourse filing.